Hallmark Capital Management Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 149,160 shares of the company’s stock after purchasing an additional 504 shares during the quarter. Johnson & Johnson makes up about 2.2% of Hallmark Capital Management Inc.’s investment portfolio, making the stock its 16th largest position. Hallmark Capital Management Inc.’s holdings in Johnson & Johnson were worth $18,099,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in JNJ. BlackRock Inc. increased its position in shares of Johnson & Johnson by 4.7% during the 1st quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock valued at $22,476,102,000 after purchasing an additional 7,853,141 shares during the last quarter. Cornerstone Wealth Management LLC increased its position in shares of Johnson & Johnson by 10,307.6% during the 2nd quarter. Cornerstone Wealth Management LLC now owns 2,497,098 shares of the company’s stock valued at $20,537,000 after purchasing an additional 2,473,105 shares during the last quarter. Bank of Montreal Can increased its position in shares of Johnson & Johnson by 36.1% during the 2nd quarter. Bank of Montreal Can now owns 6,910,459 shares of the company’s stock valued at $838,515,000 after purchasing an additional 1,833,622 shares during the last quarter. Summit Trail Advisors LLC increased its position in shares of Johnson & Johnson by 11,692.6% during the 1st quarter. Summit Trail Advisors LLC now owns 1,767,832 shares of the company’s stock valued at $1,768,000 after purchasing an additional 1,752,841 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado increased its position in shares of Johnson & Johnson by 212.7% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 1,498,023 shares of the company’s stock valued at $181,770,000 after purchasing an additional 1,019,002 shares during the last quarter. Hedge funds and other institutional investors own 66.06% of the company’s stock.

In other Johnson & Johnson news, CEO Alex Gorsky sold 264,465 shares of the stock in a transaction that occurred on Friday, November 16th. The stock was sold at an average price of $145.96, for a total value of $38,601,311.40. Following the completion of the sale, the chief executive officer now owns 481,254 shares in the company, valued at approximately $70,243,833.84. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the sale, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 349,805 shares of company stock valued at $50,593,707. Company insiders own 0.22% of the company’s stock.

Shares of JNJ stock opened at $141.99 on Thursday. The stock has a market cap of $392.91 billion, a P/E ratio of 19.45, a P/E/G ratio of 2.29 and a beta of 0.58. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.75. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The company had revenue of $20.35 billion during the quarter, compared to analysts’ expectations of $20.05 billion. During the same period in the prior year, the business posted $1.90 EPS. Johnson & Johnson’s quarterly revenue was up 3.6% compared to the same quarter last year. As a group, equities research analysts expect that Johnson & Johnson will post 8.16 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be issued a $0.90 dividend. This represents a $3.60 annualized dividend and a yield of 2.54%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 49.32%.

Several equities research analysts recently weighed in on the company. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a report on Tuesday. HC Wainwright restated a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Credit Suisse Group set a $149.00 target price on Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, October 14th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Finally, Citigroup increased their target price on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $143.97.

COPYRIGHT VIOLATION NOTICE: This article was reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/11/22/hallmark-capital-management-inc-purchases-504-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Consumer behavior in bull markets

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.